Guillaume Babin is an expert in Oncology at Institut Bergonié (France). Guillaume Babin has authored 47 publications, the most recent in 2026, and is an investigator in 2 clinical trials, 1 of them ongoing. SLR score: 132 (community average: 125). How the SLR is computed.

LeadR Profile

Guillaume Babin Institut Bergonié France
132 ScienceLeadR Reputation 132
Network Map

Oncology

Subspecialties: Gynecology - Surgery - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2015 - 2026

Source: PubMed

University of Bordeaux

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 47

Citations

Citations: 137 1st author: 2 Last author: 2 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Complementary intra- and extracellular AGR2 activities support epithelial ovarian cancer cell aggressiveness.
PMID 42575981 — oncogenes, cells, stress, physiological, ovary, neoplasms, ovarian neoplasms, carcinoma, ovarian epithelial
Oncogene20260
Development of a Rapid and Sensitive EnLIGHT OMEGA assay for extracellular AGR2 Detection in Biological Fluids.
PMID 42269775 — cells, drug discovery, neoplasms
SLAS Discov20260
Fertility preservation in gynecologic oncology: evaluating knowledge, practices, and barriers among French healthcare providers.
PMID 41494211 — fertility, genital neoplasms, female, fertility preservation, cryopreservation, oocytes, health personnel, tissues, reproductive medicine
Int J Gynecol Cancer20250
Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response.
PMID 41057919 — pharmaceutical preparations, ovary, neoplasms, drug therapy, organoids, ovarian neoplasms, genomic instability, medical oncology, chemotherapy
J Exp Clin Cancer Res20256
Results of a National French Survey on use of KELIM model for management of patients with advanced stage epithelial ovarian cancer (SFOG Campus).
PMID 40651899 — ovary, neoplasms, bevacizumab, maintenance, ovarian neoplasms, therapeutics, carcinoma, ovarian epithelial
Bull Cancer20250

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 1
Phase 3 1

By status:

Completed 1
Recruiting 1

By type:

Interventional 1
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 1

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
PARa aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
NCT05581121 — radiotherapy, carcinoma, adenosquamous, lymph nodes, lymph node excision, uterine cervical neoplasms, brachytherapy, neoplasms, adenocarcinoma, laparoscopy, human papillomavirus 16, lymph, therapeutics, carcinoma
Phase 3Recruiting2023

LeadR Networks

Main global connection map